Article
Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2020
Cheng Ying, Ma Lixia, Liu Ying, Zhu Jing, Xin Ying, Liu Xianhong, Wang Ying, Zhang Tingting, Yang Changliang, Wang Sheng, Cui Hongxia, Zhang Liang, Dai Jixin, Shao Lin, Lin Jing, Ye Junyi, Liu Hao
Abstract excerpt
OBJECTIVES: Although the majority of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients respond to EGFR tyrosine kinase inhibitors (TKIs), significant heterogeneity in clinical response is observed which might be attributed to the distinct sub-molecular characteristics. The present study aims to identify genetic alterations correlated with clinical outcomes and treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
